Tirzepatide and liraglutide sit at opposite ends of the modern incretin era. Liraglutide is an earlier, daily GLP-1 agonist; tirzepatide is a once-weekly dual GIP/GLP-1 agonist with markedly greater weight loss in trials. The contrast is both mechanism (one receptor vs two) and convenience (daily vs weekly).
At a glance
| Tirzepatide | Liraglutide | |
|---|---|---|
| Drug class | Dual GIP + GLP-1 agonist | GLP-1 receptor agonist |
| Brand names | Mounjaro, Zepbound | Victoza, Saxenda |
| FDA status | Approved | Approved |
| Dosing frequency | Once weekly | Once daily |
| Typical trial weight loss | ~20–22% | ~6–8% |
| Mechanism | GIP + GLP-1 | GLP-1 only |
| Main side effects | GI: nausea, diarrhea | GI: nausea, diarrhea |
The bottom line
Bottom line: Tirzepatide is the newer, more potent, more convenient option — once weekly with roughly triple the average weight loss of daily liraglutide in trials. Liraglutide remains an approved, well-understood choice whose shorter action suits some clinical situations. Both are prescription medicines.
Frequently asked questions
Is tirzepatide more effective than liraglutide?
In trials tirzepatide produced far greater average weight loss (~20–22% vs ~6–8%) and is dosed weekly rather than daily. Liraglutide is still an effective, approved option.
Why is liraglutide daily but tirzepatide weekly?
Liraglutide has a shorter duration requiring daily injection, while tirzepatide was engineered for once-weekly dosing. Tirzepatide also engages a second receptor (GIP).
Are both FDA-approved for weight loss?
Yes — both have approvals for chronic weight management (Zepbound and Saxenda respectively) in addition to diabetes indications, used under medical supervision.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. Peer-reviewed study
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. Peer-reviewed study
- Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025. Peer-reviewed study
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023. Peer-reviewed study
- Zhao L, Cheng Z, Lu Y, et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024. Peer-reviewed study
- Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024. Peer-reviewed study
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). N Engl J Med. 2015. Peer-reviewed study
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016. Peer-reviewed study
- Guo T, Yan W, Cui X, et al. Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis. Mol Med. 2023. Peer-reviewed study
- Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014. Peer-reviewed study
- Ni XY, Feng XJ, Wang ZH, et al. Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway. Acta Pharmacol Sin. 2024. Peer-reviewed study
- Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020. Peer-reviewed study